EMA – Page 136 – Pharma.Tips

Assay OOS during inspection prep: regulatory communication strategy

“`html Regulatory Communication Strategy for Assay OOS During Inspection Preparation In the realm of pharmaceutical manufacturing, Out of Specification (OOS) results during inspection preparation present a significant concern, especially when…

Chain of custody breach during controlled drug manufacturing: CAPA and security controls

Addressing Chain of Custody Breaches in Controlled Drug Manufacturing: A Comprehensive Investigation Guide Chain of custody breaches during controlled drug manufacturing are serious concerns that can compromise product integrity, regulatory…

Residue limit non-compliance in veterinary product manufacturing: risk assessment for animal and food safety

Addressing Residue Limit Non-Compliance in Veterinary Product Production: A Comprehensive Investigation Guide In the pharmaceutical manufacturing sector, particularly for veterinary medicines, compliance with residue limits is crucial not only for…

Diversion risk signal during warehousing: regulatory enforcement risk mitigation

Mitigating Regulatory Enforcement Risks from Diversion Signals during Warehousing In the pharmaceutical industry, the handling of controlled substances is a critical process that requires strict adherence to Good Manufacturing Practice…

Microbial limits failure in veterinary product manufacturing: GMP investigation and CAPA

Investigating Microbial Limits Failures in Veterinary Product Manufacturing In pharmaceutical manufacturing, particularly in veterinary product manufacturing, maintaining stringent microbial limits is fundamental to ensure product safety and efficacy. However, there…

Inventory reconciliation mismatch during controlled drug manufacturing: CAPA and security controls

Understanding and Addressing Inventory Reconciliation Mismatch in Controlled Drug Manufacturing Inventory reconciliation mismatch during controlled drug manufacturing presents significant challenges for pharmaceutical companies, typically manifesting as deviations, Out of Specification…

Stability failure during inspection prep: risk assessment for animal and food safety

Assessing Stability Failures During Preparation for Inspections: A Comprehensive Investigation Guide In the landscape of pharmaceutical manufacturing, particularly for veterinary medicines, stability failures that manifest during inspection prep can present…

Diversion risk signal during warehousing: inspection-ready documentation

Diversion Risk Signals During Warehousing: Essential Documentation for Compliance The proper handling of controlled substances is critical for maintaining compliance in pharmaceutical manufacturing. When diversion risk signals arise during warehousing,…

Residue limit non-compliance in veterinary product manufacturing: regulatory communication strategy

Investigation of Residue Limit Non-Compliance in Veterinary Product Manufacturing: A Comprehensive Approach The manufacturing of veterinary products is subject to rigorous standards, especially concerning the limits of residual substances. When…

Chain of custody breach during DEA/FDA inspection: regulatory enforcement risk mitigation

Mitigating Regulatory Risks in Case of a Chain of Custody Breach During DEA/FDA Inspections In the highly regulated environment of pharmaceutical manufacturing, a chain of custody breach during a DEA…

Assay OOS in veterinary product manufacturing: GMP investigation and CAPA

Investigating Assay OOS in the Manufacturing of Veterinary Products: A GMP Approach Assay Out of Specification (OOS) results in veterinary product manufacturing can signal potential quality concerns that may jeopardize…

Diversion risk signal during DEA/FDA inspection: inspection-ready documentation

Identifying Diversion Risk Signals During DEA/FDA Inspections: A Comprehensive Approach Pharmaceutical manufacturing facilities operate under stringent regulatory oversight, particularly when dealing with controlled substances. Signals that suggest potential diversion risks…